Slingshot Insights | Adro Overview

ADRO Overview

Upcoming Projects (ADRO)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (ADRO)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ADRO)

Aduro Biotech (ADRO) expects to submit an IND filing for Anti-PD1 cancer treatment in the first half of 2018
Ticker: ADRO
Occurred on: Jun 02, 2019
Aduro Biotech (ADRO) expects to submit an IND filing for antibody therapy Anti-CTLA4 in the first half of 2018
Ticker: ADRO
Occurred on: Aug 27, 2018
Aduro Biotech (ADRO) to assess Phase 1 results of ADU-741 in treatment of prostate cancer, receive Phase 2 decision, in second half of 2017
Ticker: ADRO
Occurred on: Jul 30, 2018
Aduro Biotech (ADRO) expected to initiate Phase 1b/2 trial of ADU-214/JNJ-64041757 in lung cancer in 2017 (Partnership with Janssen)
Tickers: ADRO, JNJ
Occurred on: Jun 07, 2018
Aduro Biotech (ADRO) is set to initiate ADU-214 and aPD-1 combination trial, testing pair as treatment of lung cancer, in second half of 2017
Ticker: ADRO
Occurred on: Jun 07, 2018
Aduro Biotech (ADRO) ADU-S100, a treatment for multiple tumors, expecting Phase 1 monotherapy data in the second half of 2017
Ticker: ADRO
Occurred on: Apr 17, 2018
Aduro Biotech (ADRO) to launch Anti-APRIL treatment for tumor growth and immune suppression in multiple myeloma, with Phase 1 trial set to begin in 2017
Ticker: ADRO
Occurred on: Mar 01, 2018
Aduro Biotech (ADRO) to file IND for Anti-APRIL treatment for tumor growth and immune suppression in multiple myeloma, in second half of 2017
Ticker: ADRO
Occurred on: Nov 14, 2017
ADRO Gastrointestinal cancer treatment pLADD to be evaluated in Aduro phase 1 trial, which will begin in first half of 2017
Ticker: ADRO
Occurred on: Sep 27, 2017
Aduro Biotech (ADRO) running combination ADU-S100 and aPD-1, a combined treatment for multiple tumors, launching Phase 1b combination data in the second half of 2017
Ticker: ADRO
Occurred on: Sep 26, 2017
Aduro Biotech (ADRO) is set to initiate CRS-207 and aPD-1 combination trial, testing pair as treatment of mesothelioma, in second half of 2017
Ticker: ADRO
Occurred on: Jun 28, 2017
FDA Lifts Partial Clinical Hold on Aduro's (ADRO) LADD Programs
Ticker: ADRO
Occurred on: Nov 21, 2016
Phase 2b interim data of CRS-207, GVAX Pancreas and nivolumab - STELLAR trial for Pancreatic cancer to be released 2H 2016
Ticker: ADRO
Occurred on: Nov 17, 2016
Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100
Ticker: ADRO
Occurred on: Nov 07, 2016
FDA Places Partial Clinical Hold on Aduro's (ADRO) LADD Program Due to Possible Listeria Infection
Ticker: ADRO
Occurred on: Oct 24, 2016
Aduro Biotech (ADRO) Presents Encouraging Preclinical Data Showing Combination Synergy of its Immunotherapy and Checkpoint Inhibitors to Increase Antitumor Efficacy
Ticker: ADRO
Occurred on: Sep 27, 2016
Aduro Biotech Announces Phase 2b ECLIPSE Trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer who had failed at least two prior therapies in the metastatic setting
Ticker: ADRO
Occurred on: May 16, 2016
Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer
Ticker: ADRO
Occurred on: Mar 24, 2016

Strategic Initiatives (ADRO)

Don’t see a strategic initiative related to the company you care about? Create your own!